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Introduction 
First line regimens for the treatment of adult acute leukemias are 
highly effective in achieving initial remission, however, relapse is seen 
in about half of cases [1]. Around 20–30% of these cases are refractory 
to conventional treatment, becoming a challenging domain for the 
heme-oncologists [2, 3]. The primary strategy for these cases is rein-
duction chemotherapy followed by allogenic stem cell transplantation 
[4, 5]. Fludarabine, a purine nucleotide analog, has recently become the 
focus of treatment for acute leukemias and myelodysplastic syndromes 
(MDS). Its active metabolite, Fludarabine triphosphate, inhibits ribo-
nucleotide reductase with subsequent accumulation of intracellular 
cytosine arabinoside (AraC) triphosphate [6, 7]. 
The toxicity profile of Fludarabine has been shown to be acceptable 
[8], but it is often combined with additional agents to improve efficacy 
and limit untoward toxicity [9-11]. The combination of Fludarabine 
with Ara-C increases the intracellular Ara-C content by two- to 
seven-fold in leukemic cells, which has shown a positive correlation with 
remission rates [12]. Idarubicin (IDA), an anthracycline, is also added 
because of its less susceptibility to multidrug resistance compared to 
other anthracyclines in human leukemia cell lines; and have lesser 
cardiotoxicity making them favorable for heavily pretreated patients 
[13, 14]. Granulocyte colony stimulating factor (G-CSF) prior to Flu-
darabine increases the fraction of cells in cycle when they are most 
vulnerable to AraC, and enhances the incorporation of AraC into DNA 
[15, 16]. 
The synergistic action of Fludarabine, AraC and IDA with or without 
G-CSF (abbreviated as FLAG-IDA and FLA-IDA respectively) have found 
widespread use as salvage chemotherapy for refractory/relapsed Acute 
Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) 
with complete remission rates ranging from 40–60% with variable 30- 
day mortalities ranging from 4% to 9% [4, 5, 17, 18]. Additionally, a 
recent retrospective trial by Farooq et al. [19] compared outcomes in 76 
patients treated for FLAG-IDA and FLAG; and found a significant 
improvement in survival in patients treated for Fludarabine-based 
regimen without IDA [19]. 
However, a small single-center study from Pakistan by Hashmi et al. 
[20] found a much higher 30-day mortality rate of 25% (3/12 patients) 
with FLAG-IDA and similar complete remission rates (66%). Hence, the 
purpose of our study is to identify the 30-day mortality rate in a larger 
cohort of patients with ALL/AML being treated with Fludarabine-based 
regimens in a single tertiary care center in Pakistan. Additionally, we 
aim to compare outcomes in adult patients with ALL/AML being treated 
with Fludarabine-based regimens with and without G-CSF, since this 
comparison has previously been performed without the addition of IDA 
in treatment regimens [9]. We hypothesize the 30-day mortality rate 
with Fludarabine-based regimens will be lower than the previously 
published 25% and there will be a significant difference in 
post-treatment outcomes between patients being treated with FLA-IDA 
and FLAG-IDA. 
Methods 
This retrospective cohort study was reviewed and approved by the 
Aga Khan University Hospital Ethical Review Committee. Electronic 
medical records were searched from January 2015 to November 2020 
from one tertiary university hospital in Karachi. 
Study population 
Medical records were searched for male and female adult patients 
being treated with Fludarabine-based therapy for: 1) Refractory/Relapse 
ALL; 2) Refractory/Relapse AML; or 3) Acute Leukemia transforming 
from MDS and Chronic Myeloid Leukemia refractory to or relapsing after 
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first line regimen. Patients were excluded if they: 1) were <18 years or 
>60 years of age; 2) had ECOG status >2 [21]; 3) had severe organ 
damage defined as alanine transaminase (ALT) >2.0x normal or creat-
inine >2.0x normal or cardiac ejection fraction <60%; or 4) had pre-
viously been on Fludarabine-based treatment. 
Data collection 
The following demographics were extracted from medical records: 
patient age, sex, refractory/relapse acute leukemia (ALL or AML), mo-
lecular genetic risk factors (FLT3 for AML and BCR ABL for ALL), cy-
togenetic risk factor and clinical risk stratification (high or low on ALL or 
AML risk stratification score) [22, 23]. The following post-intervention 
variables were extracted: 1) complete remission on day 28 of chemo-
therapy; 2) incidence of early death (defined as death within 4 weeks of 
chemotherapy); 3) incidence of relapse at 30 days, 60 days and 90 days 
after achieving complete remission at the end of 4-week of treatment; 
and 4) toxicity profile according to the Common Terminology Criteria 
for Adverse Events (CTCAE) which included nausea, vomiting, diarrhea, 
anemia, hepatotoxicity and nephrotoxicity [24]. 
Fludarabine-based treatment regimens 
Patients were divided into the following groups based on chemo-
therapy regimen received: 
FLA-IDA: This regimen included intravenous Fludarabine given at 
30 mg/m2/day in a 30-minute infusion (for Day 1–5), then 4 h later with 
intravenous AraC at 2 g/m2/day (for Day 1–5) in a 4-hour infusion and 
intravenous IDA at 8 mg/m2/day (for Day 1–3) as a 30-minute infusion. 
These patients did not receive G-CSF throughout the course of 
treatment. 
FLAG-IDA: This regimen also included Fludarabine (30 mg/m2/day 
for Day 1–5), AraC (2 g/m2/day for Day 1–5) and IDA (8 mg/m2/day for 
Day 1–3); with the addition of subcutaneous G-CSF from Day 1 to until 
absolute neutrophil count (ANC) of 500/mL. 
Main outcome measure and definitions 
The following outcome measures are recorded: 
Complete remission: Defined as having peripheral blood counts 
within normal limits plus bone marrow blast percentage <5% at Day 28 
bone marrow biopsy. 
Relapse: Defined as having >5% blasts in the bone marrow at either 
Day 30, 60 or 90 after achieving complete remission on Day 28 bone 
marrow biopsy. 
Refractory disease: Defined as having persistence of blast cells in 
peripheral blood and/or >5% bone marrow blast cells at Day 28 bone 
marrow biopsy. 
Statistical analysis 
Analysis was based on per protocol analysis. Univariate statistics 
were performed and 30-day mortality was calculated for the entire 
sample. Patients were categorized in the following groups based on 
treatment regimens; FLA-IDA or FLAG-IDA. Group wise comparisons 
were performed, continuous variables were compared using non- 
parametric t-tests and categorical variables were compared using χ2 
test (Fisher’s Exact for group n <5). Groups were compared on initial 
presentation characteristics and post-therapy outcomes. A binary lo-
gistic regression model was built with stepwise selection to identify 
initial presentation characteristics and treatment regime that would be 
predictive of complete remission on Day 28 of chemotherapy. A Kaplan 
Meier life table stratified by treatment regime was made. Patients who 
did not have remission were labeled as failure during treatment. Patients 
who had remission on the Day 28 biopsy but had a relapse on subsequent 
follow-up visits were label as failure on Day 30, 60 or 90 post-remission 
respectively. Patients who had remission but did not have a relapse 
during the 3-month follow-up period were censored at Day 90 and 
labeled as not having failure of treatment. Survival analysis was per-
formed using a Log-rank test comparing the equity of survival functions. 
A p-value of 0.05 was considered significant and analysis was performed 
on R Programming Language [25]. 
Results 
From January 2015 to November 2020, 39 patients were diagnosed 
with refractory/ relapsing acute leukemias and were treated with 
fludarabine-based therapy. Patients were a mean of 34.6 ± 10.6 years 
(range 19 – 55 years) and were 77% male. One patient left against 
medical advice before treatment and was not included in analysis. Three 
patients died during the chemotherapy regimen and were considered as 
Early Death during intervention, leading to a 30-day mortality rate of 
8% (3/38). Out of the 38 patients, 17 were treated with FLA-IDA and 21 
were treated with FLAG-IDA. All patients had undergone bone marrow 
cytogenetics at baseline. Patients with no abnormality in karyotype were 
considered normal in cytogenetic analysis, while those with one or more 
abnormalities, including complex karyotype were counted as abnormal. 
63% (24/38) patients in the study had at least one abnormality in their 
karyotype. 
Molecular genetic risk was based on the presence of FLT3-ITD mu-
tation in acute myeloid leukemia patients and BCR-ABL fusion in acute 
lymphoblastic leukemia patients. FLT3-ITD was positive in 5% (1/19) of 
all AML patients while BCR-ABL was positive in 23.8% (5/21) of the ALL 
patients in our sample population. NPM1 mutation was found to be 
positive in 10% (2/20) of AML patients. NPM1, FLT3-ITD mutation and 
BCR-ABL fusion was performed by RT-PCR technique. Patients did not 
differ in age, sex, primary diagnosis, history of refractory disease, clin-
ical risk stratification, cytogenetic analysis or molecular genetic risk. 
Group wise patient demographics are presented in Table 1. 
When comparing outcomes between regimens, 1 patient in the FLA- 
IDA group and 2 in the FLAG-IDA group died within 4 weeks of inter-
vention; hence only 16 patients in FLA-Ida and 19 in the FLAG-Ida group 
were included in all subsequent outcome comparisons. Groups did not 
significantly differ in post-therapy outcomes or toxicity profile, except 
FLA-IDA had a significantly higher proportion of hepatotoxicity than 
FLAG-IDA (p = 0.006) post-therapy. There were no clinical features 
including co-morbidities, viral infections or underlying disease that 
could be attributed to the hepatotoxicity in the FLA-IDA group. It was an 
incidental finding that was noticed during the retrospective analysis in 
the study. Group wise outcomes are presented in Table 2. 
Table 1 
Sample group-wise demographics.   
FLA-Idan ¼ 17 FLAG-Idan ¼ 21 p- 
value 
Age 35.65 ± 10.8 
years 
34.29 ± 10.5 
years 
0.772 
Sex 5 female, 12 male 4 female, 17 male 0.703 
Primary Diagnosis 8 de novo AML 
6 de novo B-ALL 
3 de novo T-ALL 
1 secondary B- 
ALL 
9 de novo AML 
4 de novo B-ALL 
5 de novo T-ALL 












Cytogenetic Analysis 12 abnormal 12 abnormal 0.393 
Molecular Genetic Risk 2 high risk 4 high risk 0.672 







Clinical Risk Stratification 10 high risk 16 high risk 0.307  
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On logistic regression, not having a molecular genetic risk factor was 
the only significant predictor of complete remission after treatment with 
Fludarabine-based regimens. Of note, type of Fludarabine-based 
regimen was not a predictor for complete remission (β = 1.00, p =
0.309). Results of logistic regression are presented in Table 3. 
Lastly, there was no significant difference in survival between 
Fludarabine-based regimens up to Day 90 (p = 0.671). About 60% of 
patients in the FLAG-IDA group and 40% of FLA-IDA did not achieve 
complete remission after therapy, and showed similar patterns of re-
lapses up to Day 90. Kaplan Meier life table showing cumulative survival 
are presented in Fig. 1. 
Discussion 
Our retrospective study of patients with relapsed ALL or AML being 
treated with Fludarabine-based chemotherapy had several insightful 
results. With respect to our primary objective, we found a 30-day mor-
tality rate of 8%, which is much lower than the 25% reported in a pre-
vious study from a similar setting [20]. Complete remission after 
therapy was observed in half of the sample (18/35) which is consistent 
with previous studies [4, 5, 17, 18]. With respect to our secondary 
objective, we did not find any difference in survival between patients on 
Fludarabine-based regimens with and without G-CSF, however, patients 
on FLAG-IDA has a significantly higher incidence of post-treatment 
hepatotoxicity that was not observed in patients treated with FLA-IDA. 
Temporary elevation of hepatic enzymes occur in about 10–29% of 
patients receiving G-CSF, however, these return to normal once 
treatment is discontinued [26]. 
When investigating pre-treatment demographics and clinical risk 
factors that would be predictive of remission after 4 weeks of 
Fludarabine-based chemotherapy, our analysis found the presence of 
molecular genetic risk factors (FLT3 for AML and BCR-ABL for ALL) to be 
predictive of poor outcomes. FLT3 is a FMS-like tyrosine kinase gene 
mutation and is present in about 30% of patients with AML, and is 
associated with shorter remission duration and higher relapse rates 
compared with patients without the mutation [27]. Similarly, the 
presence of the fusion of BCR-ABL is present in about 30% of patients 
with ALL and is associated with a lower chance of initial treatment 
response and a lower probability of disease-free survival [28]. Other 
variables, such as clinical risk stratification, patient gender and leuke-
mia type (lymphoid versus myeloid), were showing a trend in our lo-
gistic regression, however, our sample size is not large enough to make 
meaningful conclusions. Larger, adequately powered studies are 
required in the future to investigate which demographic and clinical risk 
factors are most predictive of treatment success during the 4-week 
intervention. 
Advancements in treatment of de novo acute leukemias are under-
way. First line regimens commonly used in our setting are AraC and IDA 
as 7 + 3 regimen in AML while the UK-ALL XII protocol is used for ALL 
patients [29]. Yet, the treatment of refractory/relapsed leukemias are a 
difficult domain due to low response rate, shorter duration of remission, 
high treatment related mortality and narrow range of therapeutics 
available, and the best modality of treatment is to do an allogenic stem 
cell transplant [4, 5]. For these reasons, salvage chemotherapy like 
Fludarabine in combination with other chemotherapeutics with an 
acceptable toxicity profile is highly useful for bridging patients to stem 
cell transplant or at least help them achieve second remission that can be 
followed with consolidation chemotherapy. Novel agents for leukemias 
refractory to Fludarabine-based regimens are also underway. Blinatu-
momab is a bispecific T cell engager monoclonal antibody that is 
directed at both CD19 on precursor B cell ALL cells and CD3 on cytotoxic 
T cells. It is approved by the European Medicines Agency for treatment 
of relapsed/refractory Philadelphia chromosome (Ph) negative precur-
sor B cell ALL. The US Food and Drug Administration has also approved 
it for relapsed/refractory Ph-negative and Ph-positive precursor B cell 
AL. A phase III trial has shown significantly longer overall survival than 
chemotherapy [30]. However, the unavailability and cost of this drug is 
a major hindrance for use in low income countries. Clofarabine, a 
Table 2 







Early Death 1/17 2/21 >0.999 
Febrile 16/16 Grade 3 19/19 Grade 3 – 
Nausea 2/16 Grade 2 
1/16 Grade 3 
2/19 Grade 2 0.526 
Vomiting 1/16 Grade 3 1/19 Grade 2 0.362 
Diarrhea 1/16 Grade 3 – 0.457 
Hepatotoxicity 5/16 Grade 1 
2/16 Grade 2 
1/16 Grade 3 
– 0.006 
Nephrotoxicity – 1/19 Grade 1 
1/19 Grade 2 
0.409 
Allergy – – – 
Anemia 5/16 Grade 1 
4/16 Grade 2 
7/16 Grade 3 
6/19 Grade 1 
10/19 Grade 2 
3/19 Grade 3 
0.133 
Complete Remission after therapy 10/16 8/19 0.229 
Relapse within 90 days after 
Remission 
5/10 4/8 –  
Table 3 









Molecular genetic risk factor 
(present vs. not present) 
− 3.614 1.711 4.461 0.035 
Risk Stratification (high/ 
intermediate vs. low) 
2.131 1.098 3.765 0.052 
Cytogenetics (abnormal vs. 
normal) 
− 0.064 0.974 0.004 0.947 
Age 0.012 0.036 0.116 0.733 
Gender (male vs. female) 1.830 1.251 2.139 0.144 
Leukemia type (AML vs. ALL) 1.546 1.074 2.072 0.150 
Chemotherapy Regimen 
(FLA-IDA vs. FLAG-IDA) 
1.002 0.985 1.035 0.309 
Initial disease presentation 
(Refractory vs. non- 
refractory) 
0.563 0.989 0.324 0.569  
Fig. 1. Kaplan Meier life table stratified by Fludarabine-based treatment 
regimen. Log rank test comparing survival function χ2 = 0.18, p = 0.671. 
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second-generation purine nucleoside analogue, has shown some prom-
ising results for ALL in Phase 2 trials in the pediatric population [31], 
and has also shown activity against AML, MDS and chronic myeloid 
leukemias in blast phase [32, 33]. Nelarabine, an araguanosine 
analogue, has also shown to be very active as a single agent in relapsed 
or refractory T-lineage ALL and may also be useful for 
Fludarabine-resistant leukemias [34]. 
This study has several limitations. This is a retrospective study and 
hence we cannot determine causality, prospective trials should be 
designed in the future to control for additional factors associated with 
treatment outcomes. More studies with larger sample size and pro-
spective analysis would help us ascertain risk factors that predict the 
clinical outcomes. We also have a relatively small sample size with a 
short follow-up of 90 days after end of chemotherapy. Future studies 
should perform a longer follow-up to see the outcomes after allogenic 
stem cell transplantation. Nine patients from our sample remained in 
remission up to Day 90 after achieving complete remission on Day 28. 
However, not all patients ended up having a transplantation with the 
major limiting factor being financial issues, unavailability of matched 
donors and personal choice. These factors are common barriers to 
treatment of cancers in low- and middle-income countries [35], so it is 
not unexpected to also find them in our setting. Future studies should 
investigate the common barriers to treatment implementation for acute 
leukemias in a low-income setting. 
Conclusion 
This retrospective study found the 30-day mortality rate for 
Fludarabine-based regimens for adult acute leukemias to be 8%, com-
plete remission in 51% of the patients with an acceptable side-effect 
profile. This makes it a reasonable choice as salvage chemotherapy to 
bridge to stem cell transplant for cases with refractory/relapsed leuke-
mia. We also did not find any difference in outcomes between the two 
treatment regimens, FLA-IDA and FLAG-IDA, so both appear equally 
efficacious and safe for the treatment of refractory/relapsed acute leu-
kemias. Good efficacy and manageable toxicity profile are the ideal 
properties of this regimen and should be considered to salvage patients 
until new therapies in development are available. 
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